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J. A. KISH, MD, E. TAPAZOGLOU, MD, AND M. AL-SARRAF, MD 
Treatment of patients with squamous cell carcinoma (SCC) of an unknown primary localized to the neck 
is still controversial, particularly regarding advanced disease. We reviewed 41 such patients treated with 
surgery and/or radiotherapy (RT) (n = 25) or with combined modality treatment including chemotherapy 
(CH) (n = 16). The male to female ratio was 28 to 13, and the median age was 58 years (range, 32 to 94 
years). There were 27 (66%) patients with poorly differentiated SCC and 8 with moderately differentiated 
or well-differentiated cancer. Twenty-three (56%) patients had N3 disease, 16 (39%) had N2, and 2 had 
N1. The majority of N3 patients have been treated with CH and RT (n = 12) or with RT alone (n = 9). 
The combined CH-RT was well tolerated, with no life-threatening toxicity. The complete response (CR) 
to CH-RT was 81% (11 patients have no evidence of disease [NED] currently). The median survival time 
of this group was 37+ months. Of the 25 patients who had surgery and/or RT as their first planned 
treatment, 7 (28%) have NED currently. The median survival time of this group was 24 months. Patients 
with N3 disease who received CH had a higher CR rate and a longer survival time as compared with 
those treated with surgery and/or RT, despite a higher (N3) stage of disease. These findings warrant 
further investigation in randomized cooperative studies. 
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PPROXIMATELY 5% of patients with metastasis to A the lymph nodes of the neck have no evidence of a 
primary, despite a thorough workup. Squamous cell car- 
cinoma (SCC) and undifferentiated carcinoma are the 
most frequent histopathologic diagnoses. These tumors 
are frequently found to involve upper and middle nodes 
(>60% of cases). However, multiple or lower localizations 
are present in 15% to 30% of patients.' In the supracla- 
vicular area, the incidence of adenocarcinoma rises to 
30% and the probability of a pulmonary, breast, or gas- 
trointestinal origin is much higher. In the presence of a 
histologically confirmed diagnosis of carcinoma metastatic 
to the neck from an unknown primary, a thorough in- 
vestigation for the possible primary site should be con- 
ducted. This investigation should include physical ex- 
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amination, complete examination ofthe upper aerodiges- 
tive tract (by palpation, indirect laryngo-pharyngoscopy, 
and naso-pharyngoscopy) with biopsies of any suspicious 
lesions, barium swallow, computed tomography (CT) scan 
or radiograph of paranasal sinuses, chest radiograph, and 
bone scan. Furthermore, when these examinations are 
unremarkable, triple endoscopy under general anesthesia 
should be performed. The hypopharynx, nasopharynx, 
and base of the tongue should undergo biopsy because 
they are the most probable sites of origin of the pri- 
m a ~ ~ . ' - ~  
Careful staging of the disease is very important because 
the therapeutic approach varies depending on the dimen- 
sion and distribution of the tumor. Although the prognosis 
for patients with N 1 is relatively good and more than 70% 
of these patients are free of disease more than 3 years after 
either radiotherapy (RT)Iq4 or radical neck dissection 
(RND),' very poor therapeutic results in terms of cure 
rate and survival have been obtained for N3 or massive 
disease. The combination of RT and surgery fails to induce 
a cure in 70% of the latter group of patients (Ta- 
ble 1 ) . l 2 - l 6  
In this report, we have retrospectively analyzed the re- 
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sults obtained from this institution in the last 10 years 
when treating patients with carcinoma of an unknown 
primary localized to the neck with either traditional ap- 
proaches without chemotherapy (CH) or more aggressive 
combinations with regimens including cisplatin (CDDP). 
Materials and Methods 
From April 1976 to May 1987, 1577 patients were re- 
ferred for head and neck (H & N) tumors to the Wayne 
State University School of Medicine in Detroit. Forty- 
seven (3%) had neck metastasis from carcinoma of an 
unknown primary, excluding adenocarcinomas. Their 
records were reviewed and 4 1 were considered evaluable 
for this study. Five patients were excluded because the 
workup showed systemic dissemination of the tumor and 
one patient was excluded due to multiple complications 
before he could start the therapy. 
The following variables were studied: clinical charac- 
teristics of the patients, stage and histologic diagnosis of 
the disease, diagnostic workup, treatment, response to 
treatment, and survival. All 25 biopsies done by our group 
were carefully reexamined. The patients were divided into 
the following two major groups according to the treat- 
ment: (1) 25 who received one of three “standard thera- 
pies” (RT alone [n = 161, surgery alone [n = 21, or surgery 
followed by RT [n = 71) and (2) 16 who were treated with 
multi-technique therapy that included CH (Table 2) In 
the latter group, four patients received concomitant 
CDDP and RT to the neck, nine patients received CDDP 
and 5-fluorouracil(5-FU) followed by RT, and three pa- 
tients were treated with adjuvant CDDP and 5-FU con- 
sisting of 3 courses after surgery, 6 courses after surgery 
followed by RT, or 6 courses after surgery and RT. In the 
group treated with CH followed by RT, two patients re- 
ceived surgery before RT and two patients alternated 
CDDP and 5-FU with 2 courses of methotrexate (MTX) 
and 5-FU. Surgery always consisted of RND on the side 
where the tumor was previously biopsied. RT was given 
to all possible sites of the primary (nasopharynx, pyriform 
sinus, and base of the tongue). The RT dosage planned 
for the whole neck or supraclavicular area was 50 to 60 
Gy, increasing to 65 to 76 Gy on the metastatic site. The 
same dosages also were adopted for adjuvant RT after 
RND. One patient treated with CH-RT at the same time 
received an interstitial implant for a dose of 15 Gy. All 
patients receiving CH as part of their first planned therapy 
were treatedbetween 1982 and 1988 (13 of 16 after 1983). 
The responses to treatment were evaluated as follows: 
a complete response (CR) required no detectable disease; 
a partial response (PR) required a reduction of more than 
50% for every tumor localization; and no response (NR) 
TABLE 1. Survival of Patients With Metastatic SCC of an Unknown 
Primary Localized to the Neck Treated With Surgery and RT 
Survival 
Total N3 or 
Author/year Treatment Yrs. (%) massive 
Bame/1970i6 
Jesse/1972’ 
Coker/ 1977’ 
Nordstromf 
19796 
Jose/ 1979’ 
Ferment/ 1 9808 
Pacini/19819 
Leipzig/l98 1 lo  
Spiro/ 19832 
Carl~on/l986’~ 
Mohit-Tabatai/ 
1986” 
McCunniff/ 
198613 
Yangl 1 986 l4 
Bataini/ 198715 
S ? RT 
S, RT, S + RT 
S + RT 
S, RT, S + RT 
RT f S 
RT 
RT 
S, RT, S + RT 
S, S + RT 
RT/S t RT 
S, RT, S t RT 
RT f S 
RT 
CH 
S, RT 
3 35 
5 31 
3 53 
2 57 
5 48 
2 53 
5 29 
3 39 
5 31 
2 17 
5 5 
2 39 
5 32 
3 40 
5 50 
10 70 
5 18 
2 38 
5 37 
5 5 
5 33 
Not reported 
36% NED 
27% NED 
14% NED 
36% 
16% 
31% 
26% 
Not reported 
28% 
21% 
39% (N2-N3) 
41% (N2-N3) 
Not reported 
0% N3, 15% 
N2 
0% NED 
Not reported 
Not reported 
14-18% 
S: surgery; RT: radiotherapy; CH: chemotherapy; NED: no evidence 
of disease. 
included responses less than 50% and stable or progressive 
disease. 
Statistical Methods 
A comparison between treatment groups (CH history 
versus no CH history) by N stage was done using Fisher’s 
exact test.I7 Since there were only two Stage N1 patients 
(neither treated with CH), we combined them with Stage 
N2 patients. The following two survival outcome variables 
were analyzed survival from date of diagnosis and, for 
TABLE 2. Patients According to First Planned Therapy 
Treatment No. of patients 
RT alone 16 
S alone 2 
S + R T  7 
CDDP 100 mg/M2 (day 1, 22,43) with concurrent 
RT 4 
CDDP 100 mglM2 (day 1,22,44)* 5-FU 1000 
mg/MZ 120 hr infusion followed by RT 9 
RND followed by CDDP + 5-FU and RT 3 
R T  radiotherapy; S: surgery; CDDP cisplatin; RND: radical neck 
dissection; 5-FU: 5-fluorouracil. 
* See Materials and Methods. 
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TABLE 3. Patient Characteristics 
No. of patients 41 
Median age in yrs (range) 58 (32-94) 
Male 28 
Female 13 
Stage of disease 
N1 2 (5%) 
N2 16 (39%) 
N3 23 (56%) 
PD 27 (66%) 
MD 5 
WD 3 
NS 3 
UD 3 
Histologic Diagnosis SCC 
SCC squamous cell carcinoma; NS: not specified; W D  well differ- 
entiated; PD: poorly differentiated; MD. moderately differentiated; UD: 
undifferentiated carcinoma. 
those patients obtaining a CR (or surgically rendered free 
of disease), the disease-free interval from that date forward. 
Follow-up for survival and disease-free status was com- 
plete as of December 31, 1987. Only one patient was lost 
to follow-up (as of April 1987) and was regarded as a 
censored observation. Standard Kaplan-Meier estimates 
of the survivorship function were made, and differences 
in survival were investigated with the generalized Wil- 
coxon test.18 
Results 
Among 41 evaluable patients, 28 were men and 13 were 
women. The median age of the patients was 58 years 
(range, 32 to 94 years). Seventeen had nodes on the right 
side of the neck, 19 had nodes on the left side, and 5 had 
bilateral involvement. Four patients had only supracla- 
vicular nodes. 
The lesions were staged according to the TNM classi- 
fication (23 [56%] were N3 or N3b [>3 cm or bilateral], 
16 [39%] were N2 [>3 but <6 cm], and 2 [5%] were N1 
[Table 31). 
The histologic diagnosis was performed on the surgical 
biopsy in all cases except one that was a needle aspiration. 
Sixteen patients with the histologic diagnosis were referred 
to our institution and the slides for 11 of them were re- 
viewed before starting the treatment. Thirty-eight patients 
had SCC (27 [66%] poorly differentiated, 5 [ 12%] mod- 
erately differentiated, and 3 [7%] well differentiated). In 
three cases, the differentiation was not specified and three 
patients had undifferentiated carcinoma. The diagnostic 
workup consisted of careful evaluation of the upper aero- 
digestive tract by triple endoscopy (n = 38) or indirect 
examination, CT scan, or radiography of the chest (100%) 
and paranasal sinus (70%). 
Negative random biopsies of the nasopharynx or hy- 
popharynx were performed on more than 80% of the pa- 
tients. In nine cases, the chest radiograph showed multiple 
suspect lesions but they were not confirmed on subsequent 
examination or remained stable for more than 2 years. 
The median time interval between the first symptoms and 
the beginning of therapy was 4 months (range, 1 to 20 
months; mean, 4.8 months), without regard to stage. All 
4 1 patients were treated with curative intent. There were 
29 CR (71%) and 18 (44%) of these patients are alive 
without evidence of disease (NED). The overall median 
survival time is 35+ months (range, 1 to 100+ months) 
TABLE 4. Median Survival Time of Patients With Metastatic SCC of an Unknown Primary Localized to the Neck 
According to Response After First Planned Treatment 
No. of Stage NED Median survival 
Treatment patients N3/N2 CR 12/87 (mo) 
CDDP + RT (concurrent) 4 410 
CDDP + 5-FW + RT 9 712 
CH + CDDP + 5-FU + RT 3 112 
Total 
RND + RTb 
RT alone 
Total 
4 4 (4+-36+) 
3 3 (11+-33+) 
6' 4 30 mo (3-7 1 +) 
16 1214 13 1 1  37+ mo (2+-66+) 
8 1% 69% 
9 217 9 
16 917" 6 
2 35 mo (4-60) 
5 10 mo (1-100) 
25 11/14 15 I 24 mo (1-100+) 
60% 28% 
41 28 18 35 mo 
68% 44% 
(a) One patient expired in clinic CR during Rt (see test); (b) two pa- C R  complete response.; NED no evidence of disease; CDDP cisplatin; 
5-FU: 5-fluorouracil; RT. radiotherapy; R N D  radical node dissection. tients were treated with CH alone; and (c) two patients were Nl .  
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TABLE 5 .  Metastatic SCC of an Unknown Primary Localized to the Neck Treated With Combined Therapy Including Chemotherapy 
Response after Response after combined 
chemotherapy treatment 
No. of 
Treatment patients N3/N2 CR PR NR CR PR NR 
_ _ _ _ _ ~  
- - Concurrent CDDP + RT 4 410 4 
CDDP + 5-FU followed by RT 9 81 1 
Adjuvant RT + chemotherapy after RNDt 3 21 1 3 2 5 2 5 1 1 - - 
* Two patients received RND after RD with chemotherapy; two pa- 
CR: complete response; PR partial response; N R  no response; CDDP 
tients died after chemotherapy, one in CR and one in PRO. 
cisplatin; RT: radiotherapy; 5-FU: 5-fluorouracil; RND: radical neck 
dissection. 
as shown in Table 4 The proportion of patients with N3 
disease in the CH group was higher (75%) than that in 
the NO CH group (44%), but not significantly higher (P 
= 0.063). 
Two of the nine patients treated with surgery as first 
planned therapy are still NED at 41 months and 19 
months after surgery and surgery and RT, respectively. 
The median survival time of this group is 26 months. 
Three patients died of locoregional recurrences. A primary 
in the pyriform sinus with contralateral nodes developed 
in one patient 57 months from primary treatment (surgery 
alone). This patient died in 2 months. Two patients died 
of adenocarcinoma of the prostate at 12 months and 24 
months after RND and one died of an unknown cause 
after 60 months. 
In the group treated with RT alone, all six (38%) patients 
who obtained a CR are still alive (five NED [range, 19+ 
to 100+ months]). A primary (involving base of the tongue 
and false vocal cords) developed in two patients at 17 
months and 28 months after RT. One patient with N1 
disease had a local CR, but pulmonary metastasis devel- 
oped at the end of the treatment. Five patients were PR 
or NR; distant metastasis developed in four of them (one 
to bone and three to lungs) and no one in this group 
survived more than 12 months). Two patients died during 
RT (one of disease progression and one of respiratory 
failure). Two patients discontinued treatment because of 
no response and died within 3 months. Patients treated 
with a combination technique that included CH constitute 
the most heterogeneous group. Twelve patients (75%) were 
in CR at the end of therapy (Table 5) ,  and 1 1  (69%) of 
them are still NED as of December 3 1, 1987. The median 
survival time of the whole group is 37 months (Table 4). 
Two patients died before completing treatment (one in 
clinical CR after CH from suspected cardiac toxicity dur- 
ing the first week of RT and one NR from Staph sepsis 
after the second course of CH). One patitnt progressed 
after CDDP, 5-W, and MTX and reached a CR when 
treated with CDDP and concurrent RT. One patient had 
an epiglottic primary discovered 10 months after the last 
therapy. He was treated with total laryngectomy but had 
a lung recurrence and died of progressive disease 24 
months later. All three patients treated with adjuvant CH 
were disease-free after surgery and are still NED after at 
least 14 months. Three of four patients with supraclavic- 
ular nodes were treated without CH because of presenting 
N2 disease (two of them died at 10 months and 26 months 
out from therapy with local recurrence and bone metas- 
tasis). The remaining two patients are still alive NED at 
more than 30 months. None among this group showed 
lung or abdominal primary. 
Patients with N3 disease who received CH had a higher 
CR rate (nine of 12; 75%) and longer survival time (P 
= 0.025) than those who did not receive CH (four of 11; 
36%) (see Fig. 1) .  Patients who received CH had a higher 
CR rate (81% versus 60%) and median survival time (37+ 
months versus 24 months) than those who did not receive 
CH. This evidence is confirmed in the N3 group. 
0.1 
O ' . * ~ . . ~ ~ . ~ ~ ~ ~ . ~ l ~ ~ , ~ ~ I ~ ~ ~ ~ ~ l ~ ~ I ~ ~ I  A 12 24 36 48 60 72 84 96 108 120 132 
TIME (MONTHS) 
FIG. I .  Survival of patients only N3 disease treated with CH (-----) 
versus those patients treated without CH (-) (P = 0.025). 
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Discussion 
Metastatic SCC to the neck usually has an occult pri- 
mary origin most probably from the H & N area.' These 
tumors have a prognosis strongly related to stage of disease 
at diagnosis, regardless of whether or not the primary is 
found.2,1Y,20 However, for node metastasis from an un- 
known primary, the staging is imprecise when it is not 
related to the tumor burden. The presence of two small 
mobile bilateral lymph nodes is considered the same stage 
as a huge fixed mass, whereas prognosis and therapeutic 
options are very different.4 A second important prognostic 
factor for these tumors is the later development of a pri- 
mary that usually renders these patients incurable.',' 
The traditional treatment of SCC of an unknown pri- 
mary is still very controversial because both surgery and 
RT are effective for small lesions, but they often fail to 
provide adequate cure rates for larger tumors even when 
they are used in combination (Table 1). 
Although the use of RT may reduce the later occurrence 
of a p ~ i m a r y , ~ . ~  such an event may occur even when all 
possible sites of origin are adequately irradiated.I3 Perhaps 
this event is related to the presence of multiple primaries, 
since they occur in approximately 20% of H & N tu- 
m o r ~ . * ' - ~ ~  
Our experience in the management of SCC of an un- 
known primary localized to the neck confirms the im- 
portance of an accurate workup to stage the extent of 
disease. Due to the unusually high incidence of poorly 
differentiated SCC (24 of 25), the biopsies of these patients 
were carefully reevaluated and confirmed. A possible ex- 
planation is the occult nasopharyngeal origin for these 
tumors. However, all the biopsies of the nasopharynx were 
negative and none of the four patients with a primary 
discovered after the end oftherapy (10 to 57 months later) 
had that site involved (three were supraglottic and one 
base of the tongue). Furthermore, only one of them is still 
alive with disease that is inconsistent with nasopharynx 
(NP) primary. We did not find any notable association of 
distant metastasis and stage of disease or tumor differ- 
entiation. 
We think that the introduction of CH as part of the 
first planned therapy has great merit. A better CR rate 
(83% versus 69%) has been obtained among patients 
treated with CH, despite the higher number of "inoper- 
able" N3 diseases present in this group (Table 4). Fur- 
thermore, the patients with N3 who received CH had a 
higher CR rate and longer survival time compared with 
those with similar stage treated with other techniques 
(Fig. 1). 
To define a better therapeutic approach for carcinomas 
of an unknown primary localized to the neck, we must 
consider the combination of at least two treatment tech- 
niques for all nodal sites except N 1. However, the majority 
of the published studies conducted with the combination 
of RT and surgery failed to induce a cure rate greater than 
30% in patients with N3 d i~ease . ' -~ -~ . '~ . ' ~  A n overall sur- 
viva1 rate of 70% at 10 years has been reported by Carlson 
et aZ.,I4 but only 22% of those patients were N3 and all 
of them were resectable. The role of CH for this disease 
has been explored sporadically and not with the most ac- 
tive regimens. In the last few years, a continuous im- 
provement in response rates to CH has been obtained for 
SCC of the H & N with CDDP-containing r e g i r n e n ~ . ~ ~ . ~ ~  
For N2 and N3 disease we propose at least 3 courses of 
CDDP containing CH followed by concurrent CDDP and 
RT as first planned treatment and surgery on the residual 
disease. This is because of the synergistic action of con- 
current CDDP and RT26-28 and because surgery is the 
most effective treatment for recurrence, whereas both CH 
and RT are less effective on patients previously treated.29 
Since our results indicate a survival advaniage for pa- 
tients with extensive disease treated with CH as part of 
the initial treatment of SCC of the H & N from an un- 
known primary, this therapeutic approach should be 
tested in a national randomized trial. 
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